(Q36187030)

12 August 2017

1 reference

title

ADAM proteases, ErbB pathways and cancer (English)

1 reference

12 August 2017

Bin-Bing S Zhou

1

1 reference

12 August 2017

Jordan S Fridman

2

1 reference

12 August 2017

Xiangdong Liu

3

1 reference

12 August 2017

Steve M Friedman

4

1 reference

12 August 2017

Robert C Newton

5

1 reference

12 August 2017

Peggy A Scherle

6

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

1 reference

12 August 2017

14

1 reference

12 August 2017

591-606

1 reference

12 August 2017

6

1 reference

Matrix metalloproteinases: a tail of a frog that became a prince

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

ADAMs: modulators of cell–cell and cell–matrix interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

The ADAMs family of metalloproteases: multidomain proteins with multiple functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

The ADAMTS metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

A potential fusion peptide and an integrin ligand domain in a protein active in sperm-egg fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Human ADAM 12 (meltrin alpha) is an active metalloprotease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Expression and enzymatic activity of human disintegrin and metalloproteinase ADAM19/meltrin beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Catalytic activity of human ADAM33

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

The metzincins--topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Tumor necrosis factor-alpha converting enzyme is processed by proprotein-convertases to its mature form which is degraded upon phorbol ester stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Intracellular maturation of the mouse metalloprotease disintegrin MDC15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Cloning and characterization of ADAM28: evidence for autocatalytic pro-domain removal and for cell surface localization of mature ADAM28

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Trafficking of human ADAM 12-L: retention in the trans-Golgi network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Endogenous meltrin alpha is ubiquitously expressed and associated with the plasma membrane but exogenous meltrin alpha is retained in the endoplasmic reticulum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

TACE and other ADAM proteases as targets for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Integrin alpha5beta1 and ADAM-17 interact in vitro and co-localize in migrating HeLa cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

The cysteine-rich domain regulates ADAM protease function in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Tailoring tissue inhibitor of metalloproteinases-3 to overcome the weakening effects of the cysteine-rich domains of tumour necrosis factor-alpha converting enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Membrane-anchored growth factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Transforming growth factor-alpha and beta-amyloid precursor protein share a secretory mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Cleavage of the membrane precursor for transforming growth factor alpha is a regulated process

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Tissue inhibitors of metalloproteinases: evolution, structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Analysis of loss of adhesive function in sperm lacking cyritestin or fertilin beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Mice lacking the metalloprotease-disintegrin MDC9 (ADAM9) have no evident major abnormalities during development or adult life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Potential role for ADAM15 in pathological neovascularization in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

ADAM8 as a novel serological and histochemical marker for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Human metalloprotease-disintegrin Kuzbanian regulates sympathoadrenal cell fate in development and neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori-infected, normal, and neoplastic gastric mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

ADAM12 in human liver cancers: TGF-β-regulated expression in stellate cells is associated with matrix remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

TACE is required for the activation of the EGFR by TGF-alpha in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

ADAM17 mRNA expression and pathological features of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

ADAMs: key components in EGFR signalling and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Oncogenic growth factor receptors: implications for signal transduction therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

The role of EGF-related peptides in tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

ADAM metalloproteases and EGFR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Pulmonary hypoplasia in mice lacking tumor necrosis factor-alpha converting enzyme indicates an indispensable role for cell surface protein shedding during embryonic lung branching morphogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

TACE is required for fetal murine cardiac development and modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Phenotypic analysis of Meltrin alpha (ADAM12)-deficient mice: involvement of Meltrin alpha in adipogenesis and myogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Transmembrane TGF-alpha precursors activate EGF/TGF-alpha receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

The discovery of receptor tyrosine kinases: targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Constitutive proteolysis of the ErbB-4 receptor tyrosine kinase by a unique, sequential mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Notch signaling in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Alterations in Notch signaling in neoplastic lesions of the human cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

KUZ, a conserved metalloprotease-disintegrin protein with two roles in Drosophila neurogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

ADAM-9 is an insulin-like growth factor binding protein-5 protease produced and secreted by human osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Heterophilic interactions between cell adhesion molecule L1 and alphavbeta3-integrin induce HUVEC process extension in vitro and angiogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Constitutive and induced CD44 shedding by ADAM-like proteases and membrane-type 1 matrix metalloproteinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

The role of ADAM 15 in glomerular mesangial cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Gefitinib--a novel targeted approach to treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.591

10.1517/13543784.14.6.591

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference